Patents by Inventor Fabrizio Giordanetto

Fabrizio Giordanetto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220144840
    Abstract: A compound of Formula (I) or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.
    Type: Application
    Filed: February 6, 2020
    Publication date: May 12, 2022
    Inventors: Fabrizio GIORDANETTO, Cecily CAMPBELL-BEZAT, Albert PAN
  • Publication number: 20210069188
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Application
    Filed: March 21, 2019
    Publication date: March 11, 2021
    Inventors: Alexander M. Taylor, Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Heike Schoenherr
  • Patent number: 10934302
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: March 2, 2021
    Assignee: Relay Therapeutics, Inc.
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, W. Patrick Walters, Mark Andrew Murcko, Fabrizio Giordanetto, Eric Therrien
  • Publication number: 20200392161
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Application
    Filed: February 21, 2019
    Publication date: December 17, 2020
    Inventors: W. Patrick Walters, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, Alexander M. Taylor, Levi Charles Thomas Pierce, Mark Andrew Murcko, Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Sathesh Bhat, Kyle Konze, Markus Kristofer Dahlgren, Eric Therrien
  • Publication number: 20200308165
    Abstract: A compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.
    Type: Application
    Filed: September 12, 2018
    Publication date: October 1, 2020
    Inventors: Yibing SHAN, Venkat MYSORE, Fabrizio GIORDANETTO, Qi WANG
  • Publication number: 20200253969
    Abstract: Disclosed herein are novel compounds of formula (I) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds ad compositions of the disclosure.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 13, 2020
    Inventors: Alexander M. Taylor, W. Patrick Walters, Mark Andrew Murcko, Fabrizio Giordanetto, Eric Therrien, Sathesh Bhat, Markus Kristofer Dahlgren
  • Publication number: 20200172546
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure.
    Type: Application
    Filed: May 25, 2018
    Publication date: June 4, 2020
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, Lucian V. DiPietro, W. Patrick Walters, Mark Andrew Murcko, Levi Charles Thomas Pierce, Yong Tang, Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Sathesh Bhat, Markus Kristofer Dahlgren, Eric Therrien
  • Publication number: 20200062760
    Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds ad compositions of the invention.
    Type: Application
    Filed: October 24, 2017
    Publication date: February 27, 2020
    Inventors: Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Alexander M. Taylor, Lucian V. Dipietro, Elizabeth H. Kelley, André Lescarbeau, Mark Andrew Murcko, Levi Charles Thomas Pierce, Kelley C. Shortsleeves, W. Patrick Walters, Sathesh Bhat, Eric Therrien, Markus Kristofer Dahlgren
  • Publication number: 20190307745
    Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for suppressing tumor cell growth, ameliorating the pathogenesis of systemic lupus erythematosus, and the treatment of various other disorders, including Noonan syndrome, diabetes, neutropenia, neuroblastoma, melanoma, juvenile leukemia, juvenile myelomonocytic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, and other cancers associated with SHP2 deregulation with the compounds and compositions of the invention, alone or in combination with other treatments.
    Type: Application
    Filed: September 22, 2017
    Publication date: October 10, 2019
    Inventors: Brian K. Albrecht, Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Alexander M. Taylor, Patrick W. Walters
  • Publication number: 20110059981
    Abstract: The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: July 2, 2007
    Publication date: March 10, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Kay Brickmann, Fabrizio Giordanetto, Johan Johansson, Fredrik Zetterberg
  • Publication number: 20100137277
    Abstract: The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: January 11, 2008
    Publication date: June 3, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Thomas Antonsson, Peter Bach, David Brown, Ruth Bylund, Fabrizio Giordanetto, Johan Johansson
  • Patent number: 7723331
    Abstract: The present invention provides compounds of the class of thienopyrimidines, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, type II diabetes, Metabolic syndrome and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, and pain related disorders, and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: May 25, 2010
    Assignee: AstraZeneca AB
    Inventors: Fabrizio Giordanetto, Tord Inghardt
  • Publication number: 20100069350
    Abstract: The present invention relates to certain new pyridin analogues of Formula (I), to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: July 2, 2007
    Publication date: March 18, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Thomas Antonsson, Peter Bach, David Brown, Ruth Bylund, Fabrizio Giordanetto, Lotta Jakobsson, Johan Johansson
  • Publication number: 20090318464
    Abstract: The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: July 2, 2007
    Publication date: December 24, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Kay Brickmann, Fabrizio Giordanetto, Johan Johansson, Fredrik Zetterberg
  • Publication number: 20090286834
    Abstract: The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: July 2, 2007
    Publication date: November 19, 2009
    Applicant: AstraZeneca AB
    Inventors: Fabrizio Giordanetto, Johan Johansson
  • Publication number: 20090227555
    Abstract: The present invention relates to certain novel pyridin compounds of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-thrombotic agents etc, and processes for their preparation, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: June 23, 2008
    Publication date: September 10, 2009
    Applicant: AstraZeneca AB
    Inventors: Peter Bach, Jonas Bostrom, Kay Brickmann, Leifeng Cheng, Fabrizio Giordanetto, Robert Groneberg, Darren Harvey, Michael O'Sullivan, Fredrik Zetterberg
  • Publication number: 20090042852
    Abstract: The present invention relates to certain novel pyridin compounds of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, and processes for their preparation, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: January 4, 2006
    Publication date: February 12, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Peter Bach, Jonas Bostrom, Kay Brickmann, Leifeng Cheng, Fabrizio Giordanetto, Robert D. Groneberg, Darren Martin Harvey, Michael F. O'Sullivan, Fredrik Zetterberg, Krister Osterlund
  • Publication number: 20090018166
    Abstract: The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: January 11, 2008
    Publication date: January 15, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Kosrat Amin, Thomas Antonsson, Christoffer Bengtsson, David Brown, Ruth Bylund, Daniel Hovdal, Fabrizio Giordanetto, Johan Johansson
  • Publication number: 20080312208
    Abstract: The present invention relates to certain new pyridin analogues of Formula (I) Chemical formula should be inserted here. Please see paper copy Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-thrombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: July 4, 2006
    Publication date: December 18, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Soren Andersen, Peter Bach, Kay Brickmann, Fabrizio Giordanetto, Fredrik Zetterberg, Krister Osterlund
  • Publication number: 20080306055
    Abstract: Compounds of formula I depicted below, pharmaceutical compositions containing them, processes for preparing the compounds, and their use in the treatment of obesity, type II diabetes, metabolic syndrome, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy and related conditions, neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease, and pain related disorders. The compounds are melanin concentrating hormone receptor 1 (MCHr1) antagonists.
    Type: Application
    Filed: December 19, 2005
    Publication date: December 11, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Bryan Egner, Fabrizio Giordanetto, Tord Inghardt